GLP-1RA药物司美格鲁肽的临床研究进展
Clinical Research Progress of GLP-1RA Drug Semaglutide
洪毅颖1
作者信息
- 1. 浙江大学医学院附属邵逸夫医院 浙江 杭州 310016
- 折叠
摘要
司美格鲁肽作为多肽类降糖药,因其安全性佳、适应证广、半衰期长等优势在同类胰高血糖素样肽-1 受体激动剂药物中崭露头角,成为当前临床研究的热点.本文通过分析司美格鲁肽的安全性,介绍该药在降血糖、心血管保护和减重等多方面的研究进展,为其临床应用与合理选择提供参考.
Abstract
Semaglutide is a polypeptide hypoglycemic drug,it has stood out in its glucagon-like peptide-1 receptor agonist class because of its safety,wide indications,long half-life and other advantages,and has become a hot spot in clinical research.This article provided a reference for Semaglutide's clinical application and reasonable selection by analyzing its safety and introducing the research progress in various aspects such as hypoglycemic,cardiovascular protection and weight loss.
关键词
司美格鲁肽/胰高糖素样肽-1受体激动剂/2型糖尿病/研究进展Key words
Semaglutide/Glucagon-like peptide-1 receptor agonist/Type 2 diabetes mellitus/Research progress引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据